Investor Relations

Breaking Through the Blood-Brain Barrier

Cognos' Mission for Improved Healthcare

Cognos Therapeutics is innovating healthcare with SINNAIS™, an implantable smart pump uniting a programmable pump, intraventricular catheter, and wireless communication. Primarily targeting Alzheimer’s disease, which carries an economic burden of $340 billion annually in the U.S., SINNAIS™ effectively bypasses the blood-brain barrier. It also addresses central nervous system (CNS) diseases such as Leptomeningeal Carcinomatosis (LC), pancreatic cancer, and glioblastoma. The combined treatment market for these CNS-related cancers is approximately $15.8 billion annually, including $6 billion for LC, $8 billion for pancreatic cancer, and $1.8 billion for glioblastoma. With SINNAIS™, Cognos addresses critical treatment gaps, underscoring its potential in Alzheimer’s and these challenging cancer treatments.